Search Results - "de Sousa Alves, Pedro Miguel"

Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study by Pujol, Jean-Louis, De Pas, Tommaso, Rittmeyer, Achim, Vallières, Eric, Kubisa, Bartosz, Levchenko, Eugeny, Wiesemann, Sebastian, Masters, Gregory A, Shen, Robert, Tjulandin, Sergei A, Hofmann, Hans-Stefan, Vanhoutte, Nicolas, Salaun, Bruno, Debois, Muriel, Jarnjak, Silvija, De Sousa Alves, Pedro Miguel, Louahed, Jamila, Brichard, Vincent G, Lehmann, Frédéric F

“…Adjuvant platinum-based chemotherapy is standard treatment for surgically resected stage II to IIIA NSCLC, but the relapse rate is high. The preferentially…”
Get more information

A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer by Curigliano, Giuseppe, Romieu, Gilles, Campone, Mario, Dorval, Thierry, Duck, Lionel, Canon, Jean-Luc, Roemer-Becuwe, Celia, Roselli, Mario, Neciosup, Silvia, Burny, Wivine, Callegaro, Andrea, de Sousa Alves, Pedro Miguel, Louahed, Jamila, Brichard, Vincent, Lehmann, Frédéric F.

“…The objectives of this phase I/II study (NCT00140738) were to evaluate the safety and clinical activity of a cancer immunotherapeutic agent (recombinant HER2…”
Get full text

A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors by Limentani, Steven A., Campone, Mario, Dorval, Thierry, Curigliano, Giuseppe, de Boer, Richard, Vogel, Charles, White, Shane, Bachelot, Thomas, Canon, Jean-Luc, Disis, Mary, Awada, Ahmad, Berlière, Martine, Amant, Frédéric, Levine, Ellis, Burny, Wivine, Callegaro, Andrea, de Sousa Alves, Pedro Miguel, Louahed, Jamila, Brichard, Vincent, Lehmann, Frédéric F.

“…This Phase I dose-escalation study (NCT00058526) assessed the safety and immunogenicity of an anti-cancer immunotherapeutic (recombinant HER2 protein (dHER2)…”
Get full text

Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic by Baurain, Jean-François, Robert, Caroline, Mortier, Laurent, Neyns, Bart, Grange, Florent, Lebbe, Céleste, Ulloa-Montoya, Fernando, De Sousa Alves, Pedro Miguel, Gillet, Marc, Louahed, Jamila, Jarnjak, Silvija, Lehmann, Frédéric F

“…PurposeThis study assessed clinical activity, safety and immunogenicity of MAGE-A3 immunotherapeutic in patients with MAGE-A3-positive metastatic…”
Get full text